Affordable Access

Publisher Website

Intermediate-term results of a prospective, multicenter study on remote programming sacral neuromodulation for refractory overactive bladder.

  • Zhang, Yaoguang1, 2
  • Meng, Lingfeng1, 2
  • Zhang, Peng3
  • Tian, Xiaojun4
  • Chen, Guoqing5
  • Li, Yan6
  • Zhang, Yong7
  • Xu, Zhihui8
  • Wei, Zhongqing9
  • Zhang, Wei2
  • Ma, Lulin4
  • Shi, Benkang6
  • Liao, Limin5
  • Wang, Jianye1, 2
  • 1 Urology Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing, China. , (China)
  • 2 Peking University Fifth School of Clinical Medicine, Beijing, China. , (China)
  • 3 Urology Department, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. , (China)
  • 4 Urology Department, Peking University Third Hospital, Beijing, China. , (China)
  • 5 Urology Department, China Rehabilitation Research Center, Beijing, China. , (China)
  • 6 Urology Department, Qilu Hospital, Shandong University, Jinan, China. , (China)
  • 7 Urology Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. , (China)
  • 8 Urology Department, Zhejiang Provincial People's Hospital, Hangzhou, China. , (China)
  • 9 Urology Department, Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. , (China)
Published Article
Translational andrology and urology
Publication Date
May 01, 2021
DOI: 10.21037/tau-21-43
PMID: 34159077


To evaluate the efficacy and safety of a novel remote programming sacral neuromodulation (SNM) system (BetterStim system) in the treatment of patients with refractory overactive bladder (OAB) for 3 years. A total of 8 centers in China enrolled 84 patients with OAB. Following test stimulation 70 patients underwent implantation using BetterStim. All patients returned for follow-up at 3 and 6 months postoperatively. After that, the visits were conducted by telephone. Outcomes of voiding diaries, the overactive bladder symptom score (OABSS), questionnaires regarding OAB-related quality of life (OAB-qol), and adverse events (AEs) were evaluated at each visit. The clinical therapeutic success was defined as ≥50% improvement from baseline in any of the voiding diary variables or average voids/day return to normal voiding (<8 voids/day). The analysis is a modified Completers analysis. At the 36-month follow-up, the success rate was 79% for overall OAB symptoms, 69% for urge urinary incontinence (UUI) and 42% for urgency frequency (UF). The average number of voids/day decreased from 29.2±14.9 at baseline to 17.6±11.2 at 3 years, the average volume/void increased from 94.7±54.2 to 151.4±80.8 mL, the urgency reduced from 3.0±1.4 to 1.8±1.7 (all P<0.001). For patients with urge incontinence, mean leaking episodes/day decreased from 8.1±7.6 at baseline to 2.1±3.5 at three years (P<0.05). The devices were explanted in 8 (11.4%) patients. There were no remote programming-related AEs or device-related serious AEs that occurred. The Intermediate-term results demonstrated that BetterStim SNM system with remote programming is safe and effective for patients with refractory OAB. 2021 Translational Andrology and Urology. All rights reserved.

Report this publication


Seen <100 times